BioBAY微信订阅号
BioPOS微信服务号
Customers
×
BeiGene is a globally focused biopharmaceutical company dedicated to becoming a leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer. We believe the next generation of cancer treatment will utilize therapeutics both as monotherapy and in combination to attack multiple underlying mechanisms of cancer cell growth and survival. Our lead product candidates are BGB-3111 and BGB-A317. BGB-3111 is a potent and highly selective small molecule BTK inhibitor that is currently being evaluated in dose expansion clinical trials as a monotherapy and in combination with other therapies to treat various lymphomas. BGB-A317 is a humanized monoclonal antibody against the immune checkpoint receptor PD-1. It is believed to be differentiated from the currently approved PD-1 antibodies with the ability to bind Fc gamma receptor I specifically engineered out, and has the potential to restore a T-cell’s cancer killing ability by inhibiting PD-1 and removing the blockade of immune activation against cancer. We also have other clinical stage assets, including BGB-290 and BGB-283. BGB-290 is a molecularly targeted, orally available, potent and highly selective inhibitor of PARP1 and PARP2. BGB-290 has the potential to be differentiated from other PARP inhibitors, including olaparib, the only PARP inhibitor currently approved by the FDA and the EMA, in terms of selectivity, DNA-trapping activity, oral bioavailability and brain penetration. BGB-283 is a small molecule RAF kinase inhibitor which is also currently being evaluated in dose expansion clinical trials as a monotherapy and in combination with other therapies to treat cancers with aberrations in the mitogen-activated protein kinase, or MAPK, pathway, including BRAF gene mutations and KRAS/NRAS gene mutations where first generation BRAF inhibitors are not effective. We have a global team of 310+ employees and consultants, including more than 200 talented scientists and clinicians, with deep scientific knowledge, extensive pharmaceutical experience, and a commitment to improving the lives of cancer patients globally. We have offices and facilities established around the world, including global clinical headquarter in San Francisco (Emeryville and San Mateo) and additional clinical facilities in Australia, Beijing, and Shanghai, R&D center in Beijing, manufacturing sites in Suzhou and Guangzhou, and operations in Boston and Beijing.
×
BrightGene Bio-Medical Technology Co., Ltd. locates next to the beautiful Dushu Lake at Suzhou Industrial Park. As the one awarded with "National High-Tech Company", "Jiangsu Innovative Company", "Jiangsu Provincial Engineering and Technology Research Center of Drug with Multiple Chiral Centers" and "Financial Rating AAA" etc. awards or nominations, BrightGene dedicates itself on research, develop and industrialize of high-end drug substances and products, serves global customers with high-class products and technologies, based on the professional develop ability and excellent business philosophy. With the support of national, provincial and district government, BrightGene has achieved more than 100% annual growth rate since its foundation to a group incorporating 4 wholly-owned subsidiaries: 6000 m2 – research institute, 3000 m2 – pilot plant, 6000 m2 – GMP facility at Suzhou Industrial Park, 2000 m2 – fermentation R&D center at Chongqing and 20,000 m2 – front-end production base at Taixing. Now the company has become a great pharmaceutical corporation with complete industry chain of research, development, production and marketing. These remarkable achievements attracted many institutional investors like Lilly Asia Fund. BrightGene invested not less than 30 percent of annual revenue in research and development study, and R&D personnel account for near 70% of total 500 employees. The research institute has acquired more than 100 HPLC, introduced state-of-the-art equipment such as NMR, LC-MS and AAS, and established the research platforms for multi-chiral, polysaccharide, semi-synthetic APIs and novel drug delivery systems such as hot-melt extrusion, nano intravenous iron, etc. The company has files 154 patent applications, 36 of them are authorized and 12 of them are the PCT patents.
×
The company is in clinical stage, engaged in new generation of precise antibacterial drug research and development, dedicated to filling the domestic and foreign major medical needs. The new research and development platform of the dual-target molecular new drug, which is unique, is committed to solving the major challenges of antimicrobial resistance.
×
Hutchison MediPharma (HMP) is an innovative biopharmaceutical company based in China and the Innovation platform of its parent company, Hutchison China MediTech Limited (HCM). Established in 2002, HMP is aiming to become a global leader in the discovery, development and commercialization of targeted therapies for oncology and immunological diseases. HMP, has a large scale and fully-integrated in-house research and development (R&D) team of over 300 scientists and staff, which has developed and progressed a broad pipeline of novel oral drug candidates for cancer and inflammation. HMP’s R&D team use a chemistry-focused approach to develop highly selective small molecule tyrosine kinase inhibitors that are intended to have global first-in-class efficacy or be sufficiently differentiated to be global best-in-class, next generation therapies with a superior profile compared to existing approved drugs that act against the relevant kinase targets. These novel oral compounds for cancer and inflammation are currently in development in North America, Europe, Australia and Greater China and are deliberately engineered to improve drug exposure and reduce known class-related toxicities. Our strategic partnerships have involved global, innovative companies such as AstraZeneca, Johnson & Johnson, Eli Lilly, Merck Serono and Nestlé Health Science in both oncology and inflammation.
×
Focus on the development of innovative drugs in respiratory diseases, various drug-resistant bacteria and viral infections diseases, digestive tract, pain and cardiovascular diseases. Major research and development projects are innovative drugs such as Revefenacin, Axelopran, Cefilavancin, td-1607 and td-9855. Among them, td-1607 and td-9855 have obtained the "fast-track" license for new drug development of FDA and are now preparing for phase ii clinical trials. Other products have completed phase ii clinical trials and are in phase iii clinical trials.
×
Levena Biopharma was founded in June 2016, China. The company licensed site-specific antibody-drug conjugation technology (C-lock, K-lock) from Concortis Biosystem (now part of Sorrento Therapeutics), along with its proprietary toxin payloads to develop novel antibody-drug conjugate (ADC) therapeutics to address unmet medical needs worldwide. We have partnered with 3 biotech and pharmaceutical companies to advance our ADC projects, which we are looking forward to moving them into IND studies. In our Nanjing facility, we have also established state-of-the-art laboratories to produce toxin, linker and toxin-linker on large scale.
×
MabSpace Biosciences, is a biotech company focused on discovery and development of innovative antibody based therapeutics for cancer and fibrotic diseases. It was founded in 2013 by indrustrial veterans and is located in Biobay Suzhou, an emerging bitech incubator in China. MabSpace employes its proprietary platform technology, immune tolerance breaking technology (IMBT), to generate lead antibodies with diverse epitopes. MabSpace has established multiple antibody discovery and co-development partnerships based on this technology. MabSpace raised 15 million USD from Lilly Asia Ventures in 2015 to advance its lead antibody program, a potentially best-in-class anti-PD-L1 antibody with unique pH-dependent binding and recycling property and significantly improved efficacy in animal models. It has also built a panel of 2nd generation immuno-oncology antibodies targeting different components of the tumor microenvironment,which enables the testing of combination therapeutic interventions with its PD-L1 antibody. MabSpace has established a pipeline of therapeutic antibodies targeting various compoents of the tumor microenvironment. The lead asset is a second generation blocking PD-L1 ab with unique pH-dependent antigen binding and recycling properties. To enable combination therapy, MabSpace has developed antibodies targeting angiogeneic receptor VEGFR2, agonist antibody targeting OX40 for enhancing T cell activities and suppressing regulatory T cells, as well as antibody targeting CSF1R for the inhibition of immune suppresiion mediated by tumor associated macrophage. In addition, MabSpace has ongoing projects targeting dendritic cells and other checkpoint inhibitors.
×
PegBio Co. Ltd.is a leading biopharmaceutical company in China, specializing in manufacturing polyethylene glycol (PEG) and development of PEGylation technology leading to PEGylated drugs as putative NEW Molecule Entities (pNMEs). The Company is located at the BioBay Park in Suzhou, a beautiful city in China. Placed in a brand new building, the laboratory is equipped with the state-of-the-art equipment and devices. The Company has developed proprietary PEG synthesis technology and innovative solutions for random and site-specific PEGylation (1st and 2nd generations of PEGylation) of macromolecules. PegBio currently provides reagent-grade mPEGs to its domestic and international customers in the academic and pharmaceutical fields. The mPEGs provided vary in molecular weights (from a few hundred to 50 KDa), structures (linear, branched, as well as proprietary multiple-armed), and a variety of activation groups such as succinimidyl succinate, succinimidyl carbonate, maleimide, and aldehyde. The Company is now developing pharmaceutical grade PEGs to meet needs of PEGylated biopharmaceuticals. PegBio also provides PEGylation services by applying the random and site-specific technologies, to its strategic alliance collaborators for chemical modifications of macromolecules such as peptides, proteins, and antibody fragments. Among PegBio proprietary products, PEGylated peptides and antibody fragments for the treatment of type II diabetes and rheumatoid arthritis are being developed, respectively.
×
Repson Biotech was founded in May 2014, as the first industrialization project of National Institute of Biological Sciences, Beijing (NIBS), with the core team consisting of Academician Wang Xiaodong (leader), Zhi Gang, vice director of NIBS and Huang Niu, senior research fellow. The Company currently focuses on development of the FTO activity inhibiting weight reduction new drug, which is the only small molecular chemical synthetic drug with the definite biological target in the world now, an old drug for new purposes. According to the current research data, the drug shows the satisfactory safety and clinical efficacy, hopefully becoming a blockbuster product in the market. It plans to complete the domestic new drug application and the overseas intellectual property right transfer for the 1st generation FTO inhibitor within 3 years, to develop and market the drug in the world.
×
The company is committed to innovative therapeutic antibodies drugs, targeted recombinant proteins and small molecules targeting drug. The company is determined to provide the people with the use of the high - end biomedical products. Company has research and development of several project contracts, the establishment of a multi-layered platform with advanced drug discovery, development and production technology development, and other technology. The research of the product line covers the treatment of tumors, respiratory diseases, senile diseases and has yet to meet the demand of clinical medicine field.
×
CGeneTech, a leading drug discovery company that develops novel therapeutic agents for the treatment of unmet medical needs. Our technology platform has been designed to quickly and cost-effectively generate new leads and drugs, so that we can manage the cost of the research and discovery of new therapies. This cost-containment should allow us to pass cost savings onto our patients, while maintaining desired margins. This approach is achieved through the independent discovery, development and eventual commercialization of our own products, combined with extensive partnerships to develop and commercialize discoveries in areas in which our partners have special expertise and interests. We have structured our business to enable sustained revenues, thus minimizing some of the inherent risks in the biotech and biopharmaceutical business. We have grown our company carefully to ensure a strong foundation, aware of the need to maintain high growth potential while building a revenue-generating business. To that end, we believe that our unwavering focus on drugs, a proven approach for marketed drugs, enables us to address large potential markets. By integrating a number of scientific and drug development disciplines, we are able to efficiently discover and develop small molecule compounds, and therefore have a reduced likelihood of adverse side effects and clinical failure.
×
Ark Biosciences is a biotech startup company focusing on innovative drug discovery and development, especially in the respiratory virus field, for world-wide markets. It is headquartered in the Zhangjiang Hi-tech Park of Shanghai, the heart of pharmaceutical innovation in China. Ark Biosciences has its own active discovery programs, those of partners, and licensing in drug assets for clinical development in the Asia-Pacific region. Ark Biosciences intends to become the driving force behind China's evolution into a global innovation center for drug discovery and development. We strive to build a science-driven biopharmaceutical company that aims to be a leader in antiviral drug discovery and development. To achieve this, we strive for scientific excellence and continual innovation. We operate with razor-sharp focus and dedication, aiming to meet our deadlines in a cost efficient manner. We create a healthy and rewarding work environment for employees, and seek a superior rate of return for investors and partners.
×
Suzhou Kintor Pharmaceutical Inc. is an innovative biotech company committed to the discovery of novel medicines for treatment of oncological, cardiovascular and inflammatory diseases. Senior scientists and management of Kintor consist of professionals who have received their doctorate degrees from well-known universities in China and the United States. The company's leadership has decades of experience in managing research and development and advancing multiple new drugs into clinical trials both at home and abroad. Kintor is developing a more effective treatment of prostate cancer as well as highly potent and selective kinase inhibitors for the treatment of the most life-threatening cancers (breast, liver and lung) and inflammatory diseases such as rheumatoid arthritis. Kintor scientists are working tirelessly to complete pre-clinical development for their most advanced programs and to move the new medicines into clinical trials within the coming one to two years. During the process, Kintor will establish a strong pipeline of innovative targeted therapeutics supported by a world-class drug research and development platform spanning from early research, preclinical development and clinical development to market. Our ultimate goal is to establish Kintor as an internationally competitive pharmaceutical company.
×
Kangju Bio Technology Co. Ltd. is a core technology of conjugation. The company established a desired expression platform based on E. coli and mammalian cells, small scale research and pilot processes and hardware devices. Kangju Bio has established and perfected the technology platforms, including glycosylation engineering technology platforms, antibody-drug conjugates technology platform, the proposed small molecule expressed in E. coli antibody technology platform and innovative bispecific molecule drug development technology platform. Using this technology platform, Kangju successfully developed dozens of recombinant protein drugs, including two long-acting recombinant glycoprotein drugs and several recombinant monoclonal antibody drugs.
×
Alphamab Co. Ltd was established in early 2009 by Dr. Ting Xu, recipient of prominent “Thousand Talent Program”. Since its inception, the company has been striving to become a leader in booming biotech industry in China. The R&D center in Suzhou occupies over 60,000 square feet lab and office space. Now the center has over 100 talented scientists, more than 60% of which hold graduate degrees. In past few years, Alphamab has formed strategic alliance with Shanghai Institute of Materia Medica, Chinese Academy of Science, Southeast University and Thermo Scientific as part of its open drug discovery platform. The platform is supported by a world class scientific advisory board and active collaborations with major pharmaceutical companies in China. So far, over 300M RMB has been invested in infrastructure and advanced instruments. The center is fully equipped for biologics R&D, from target validation, hit screening, H2L, PK/PD, pharmacology, cell line construction, process development, scale up GMP manufacturing and IND filing. The BDS and FFP suites, built to meet cGMP requirement of CFDA, FDA and EMA, were commissioned in 2013 and certified by Jiangsu CFDA for biologics manufacturing in 2014. Currently there are more than 30 active projects in Alphamab, including biosimilars, novel mAbs and engineered version of mAbs and proteins. Through internal effort and external collaboration, Alphamab is successfully entering oncology, infertility and blood disorder area with two filed INDs, 3 pending INDs and dozens at earlier stages.
×
Kelun Pharmaceutical Southern Institute (Suzhou Kelun Pharmaceutical Research Co. Ltd.), founded in October 2013, with the newly-added investment of RMB200 million, and the team of 700 persons (to reach the size within 3 years, in which 90% with the bachelor's degree or above and 40% with the master's degree or above) shall establish more than 10 departments, e.g. generic and innovative drug development, pharmacological and clinical research, project registration and comprehensive management, etc., and form the complete research and development system from raw material synthesizing to project filing. It shall cooperate with the R&D centers in Chengdu and Tianjin, and become the first class research and development institution for innovative drugs with high technical content in China.
×
Sirnaomics is leveraging an unsurpassed level of knowledge and experience in RNA interference (RNAi) technology and forging a path to high value creation with exciting clinical product development programs in multiple therapeutic areas. Sirnaomics, Inc. was established in 2007 by a group of leading scientists from top US pharmaceutical companies. Our management team has combined over 100 years experience in the biopharmaceutical industries with special expertise in RNAi and delivery system technologies. We have partnered with NIH, NAVY MRC, Johns Hopkins, Duke, University of Maryland and Penn State University. This work has advanced our product development and preclinical programs and we are now ready to move forward with our clinical development strategy. The vast experience of our scientific and management teams ensures that our therapeutics are developed with the highest quality of scientific validity and supported by a solid intellectual property portfolio. We feel this gives us a significant advantage in both the safety and efficacy of our therapeutics as we move forward and execute our clinical programs in US, EU, and China. Our lead product candidate STP705 is an Anti-fibrosis compound and our first indication in humans will be Hypertrophic scar reduction and prevention. Hypertrophic scarring is an abnormal condition that can occur after any injury to the skin and most commonly after surgical procedures. This abnormal scarring results in scars that are large, red, raised and pruritic. If this type of scarring occurs on the face or over joints such as the hips, knees, shoulders, or hands, it can be both disfiguring and debilitating. There is no FDA-approved therapeutic for hypertrophic scar prevention and reduction and currently used off label treatments typically have been show to have minimal impact in terms of efficacy with very high recurrence rates. Pathophysiology of hypertrophic scars entails a prolonged inflammatory and proliferative phase of wound healing after injury. Among various cytokines promoting hypertrophic scar formation, TGF-β1 is known as a key regulator of the aberrant fibrogenic response while COX-2 acts as potent pro-inflammatory and proliferative mediator. STP705 (Cotsiranib) targets both TGFβ1 and Cox-2 gene expression and has been tested in mouse and swine skin excision wound models, and human hypertrophic scar tissue implant mouse models. STP705 has achieved simultaneous silencing of TGF-Beta1 and COX-2 expression as well as down regulation of fibrogenic markers like alpha SMA, hydroxyproline, Collagen 1 and Collagen 3 and fibroblast apoptosis in multiple animals models as well as a human hypertrophic scar model and STP705 has demonstrated therapeutic benefit of scar prevention and reduction in animal models.
×
ShengjiBio has established and perfected the technology platforms, including glycosylation engineering technology platforms, antibody-drug conjugates technology platform, the proposed small molecule expressed in E. coli antibody technology platform and innovative bispecific molecule drug development technology platform. Using this technology platform, Shengji successfully developed dozens of recombinant protein drugs, including two long-acting recombinant glycoprotein drugs and several recombinant monoclonal antibody drugs.
×
It is mainly engaged in the research and development, pilot, production and sale of biosimilar-producing drugs. The company covers an area of 130,000 square meters. The company has established advanced experiment and workshop, and has purchased the world leading purification, ultrafiltration, analysis and other equipment.
×
Stainwei has succeeded in development of its core proprietary HexTM technology for rapid, stable and high level expression of humanized antibody and IgG-fusion protein in mammalian cells, and this technology has lead to an industrial scale production. One of its key products, an antibody with anti-angiogenesis activity, has reached to IND filing stage. In addition, there are more than 7 other innovative therapeutic antibodies in the pipeline under various stages of development.
×
Focus on the development of cancer and autoimmune disease innovation and the best antibody drugs of its kind. Core team members have first-class experience with pharmaceutical research and translational medicine research in pharmaceutical industry.
×
Suzhou Yabao pursues new drug R&D through collaboration, with an international emphasis. We collaborate with world-class companies and academic scientists on their early-stage programs, and aim to develop breakthrough new drugs with international potential utilizing the advantages China offers. In addition, moving forward we hope to collaborate as well with investors and domestic companies on our existing programs. Thus far, in the two years' short history of the company; we have established 7 international collaboration programs with world-class scientists and multinational companies. As a result, we have a rich pipeline focusing on new and novel targets. Our team has strong combined R&D experiences from both US and China. We have high operational efficiency and flexibility as a new small biotech company, but also the reliable support of a public Chinese pharmaceutical company (namely, our investor Yabao Pharmaceutical Corporation). We believe these advantages and strengths will make us the premier innovative R&D Company in China.
×
The company is committed to natural innovative drug research, development and industrialization, after years of effort, the company has achieved great development in research and development team construction, staff training. Since its inception in 2008, the company has a research and development laboratory with a full range of r&d facilities and laboratory personnel. Company cooperates with park companies, through resource integration and optimization, build a biological pharmaceutical innovation incubator. After social assessment for the early stage of the incubation, hatching a successful project for achievements.
×
Youseen Co.,Ltd is specialized in the development of proprietary pharmaceutical products including innovative drugs for cardiovascular and cerebrovascular diseases and anti-infection treatment. Youseen has so far filed for more than 80 invention IP applications and 2 PCT applications, and 26 IPs are authorized. Youseen is taking an leading position among domestic competitors owning to its capacity in new drug R&D. With the outstanding technical advantages, Youseen has undertaken a number of national/provincial technical funding projects, including 5 national projects in R&D stage and 6 provincial level projects. Among which, there are 3"The 11th Five-Year National Major Drug Discovery"projects, and 2 "MOST Enterprise Innovation Fund"projects. In order to pave the foundation for future commercialization, the company is currently building the industrial production facility in Shengpu SIP.
×
Adagene is an antibody discovery and engineering company with proprietary Smart Antibody Technology, which increases success rates, substantially accelerates time to market, and reduces the costs associated with developing a therapeutic antibody. With the mission to create a positive global impact with its technology, Adagene seeks to establish technology-driven discovery partnerships with the world's leading pharmaceutical and biotechnology companies and build therapeutic pipelines for future licensing and development. The Smart Antibody Technology strikes the fine balance between Mother Nature and human design, resulting in antibodies with enhanced safety and potency profiles. It is through this unique harmonization of natural repertoires with targeted synthetic designs that leads to the development of superior bio-therapeutics. The intrinsic limitation of current antibody technology fails in its ability to create antibodies with unprecedented precision, speed, and effectiveness. Through Smart Antibody Technology, Adagene seeks to transform the precision for antibody generation, engineering and development, with tailor-made attributes for therapeutic, diagnostic, and research applications.
×
A leading biotech company in China, Innovent Biologics, Inc. was founded in August 2011. Innovent aims to produce highly complex biopharmaceutical products that will be affordable to people in China and around the world. Backed with investments from world-class leading financial institutions totaling $240M, Innovent has established a solid foundation for growth. From its onset, Innovent has been focusing on innovation. In its first five years, Innovent built up a portfolio of 13 molecules targeted towards indications in cancer, ophthalmology, autoimmune disorders, and cardiovascular diseases. Five of Innovent’s molecules have been selected under the “national mega innovative program”. One of Innovent’s molecules was awarded a “precision medicine research” grant under the National Key R&D Plan program. From a manufacturing perspective, Innovent has built a large-scale manufacturing base, which includes two 1,000-liter bioreactors that have been in operation since 2014. Innovent also has six 3,000-liter and four 15,000-liter bioreactors that are currently in the design phase. The entire facility is in compliance with GMP Standards from the CFDA, FDA and EMA. The two 1,000-liter lines passed an MNC audit by our MNC partners in September, 2016, earning the distinction of being the first biopharmaceutical production line that complies with the FDA standards. Innovent has also been fortunate to have attracted over 50 overseas returnees, most of whom are high level professionals and talented people from across the industry, having not only deep China expertise but also having meaningful global experience as well. These high quality and knowledgeable professionals form the backbone of Innovent talent pool. In 2015, Innovent and Eli Lilly signed two collaboration agreements to co-develop and co-commercialize six antibody drugs over the next decade. The transaction not only brings upfront and potential milestone payments to Innovent well above $1.4 B, but also sets several industry precedents for Chinese biotech companies. This was the first time a biopharmaceutical product invented by a Chinese company was licensed to a Global Top 20 company while also commanding the largest upfront payment a Chinese company has received to date from a global partner.
×
GinkgoPharma(Suzhou)Co., Ltd is an innovative R&D oriented biotechnology company established in 2009 in BioBay Suzhou. The core team consists of China-based experts with over 10 years of innovative pharmaceutical R&D experience.The company also maintains long term partnership with multiple R&D institutes in China.Currently, the company focuses on the R&D of novel treatments for hepatitis virus. Looking intothe future, we strive to become the leading developer of Hepatitis Therapeutics in China.
×
Zai Lab is a Shanghai-based biopharmaceutical company. Our globally-experienced drug development team is passionate about bringing transformative medicines to China and discovering and developing our own therapeutics for patients worldwide. Our vision at Zai Lab is to create a premier drug discovery, development, manufacturing and commercialization organization built on a foundation of world-class expertise and insights into the existing and expanding needs of Chinese patients. We have assembled a team of leaders who have a collective track record in all aspects of our business, including pioneering success in the regulatory process in China. We have established a pipeline of best-in-class biopharmaceuticals at different stages of development by securing partnerships with leading multinational pharmaceutical and highly innovative biotechnology companies. Our pipeline will grow through additional collaborations and from our internal discovery and development efforts.